NeoGenomics Q3 Revenues Climb 8 Percent; Firm Amends Covance Testing Agreement | GenomeWeb

NEW YORK (GenomeWeb) - NeoGenomics today reported that its third quarter revenues increased 8 percent, just shy of Wall Street's consensus estimate. The firm also announced a change to its testing services agreement with Covance.

For the three months ended Sept. 30, revenues for the Fort Myers, Florida cancer genetic testing firm increased to $25.1 million from $23.2 million in the prior-year period. On average, analysts had expected $25.6 million in revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.